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1022Objective: Ecallantide is a recombinant peptide in the same class as aprotinin that inhibits plasma kallikrein,
a major component of the contact coagulation and inflammatory cascades. Therefore, ecallantide was expected
to reduce blood loss associated with cardiac surgery requiring cardiopulmonary bypass.
Methods: This prospective multinational, randomized, double-blind trial enrolled patients undergoing cardiac
surgery using cardiopulmonary bypass for procedures associated with a high risk of bleeding. Patients were ran-
domly assigned to ecallantide (n¼ 109) or tranexamic acid (high dose, n¼ 24; low dose, n¼ 85). Efficacy was
assessed from the volume of packed red blood cells administered within the first 12 hours after surgery.
Results: The study was terminated early after the independent data safety and monitoring board observed a sta-
tistically significantly higher 30-day mortality in the ecallantide group (12%) than in the tranexamic acid groups
(4%, P ¼ .041). Patients receiving ecallantide received more packed red blood cells within 12 hours of surgery
than tranexamic acid-treated patients: median ¼ 900 mL (95% confidence interval, 600–1070) versus 300 mL
(95% confidence interval, 0–523) (P<.001). Similar differences were seen at 24 hours and at discharge. Patients
treated with the higher tranexamic acid dose received less packed red blood cells, 0 mL (95% confidence inter-
val, 280–600), than the group treated with the lower dose, 400 mL (95% confidence interval, 0–400) (P¼ .008).
No deaths occurred in the higher dose tranexamic acid group.
Conclusions: Ecallantide was less effective at reducing perioperative blood loss than tranexamic acid. High-dose
tranexamic acid was more effective than the low dose in reducing blood loss. (J Thorac Cardiovasc Surg
2012;143:1022-9)Excessive postoperative bleeding after cardiac surgery
complicates conditions in 0.6% to 11% of patients under-
going procedures requiring cardiopulmonary bypass
(CPB).1 Hemorrhage and reoperation for bleeding signifi-
cantly increase hospital length of stay and cost of care.2,3
Transfusion of allogeneic blood products exposes patients
to risks of transfusion-related adverse effects.4
The mechanism of bleeding from CPB is multifactorial.
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Abbreviations and Acronyms
ACT ¼ activated clotting time
BART ¼ Blood Conservation Using
Antifibrinolytics in a Randomized Trial
CABG ¼ coronary artery bypass graft
CPB ¼ cardiopulmonary bypass
DSMB ¼ Data Safety Monitoring Board
FFP ¼ fresh-frozen plasma
MI ¼ myocardial infarction
PRBC ¼ packed red blood cell
WBHC ¼ whole blood heparin concentration
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Daprotinin and tranexamic acid have been shown to reduce
perioperative blood loss and the need for blood transfusion
after CPB, aprotininwas usedmorewidely in cardiac surgery
with a high risk for bleeding.12 However, aprotinin was re-
cently withdrawn from marketing because of safety con-
cerns, consequently decreasing the therapeutic options
available to attenuate blood loss in high-risk cardiac surgery.
Ecallantide is a novel, recombinant human peptide de-
rived from the first Kunitz domain of the human tissue fac-
tor pathway inhibitor-1 that inhibits the tissue factor
pathway of coagulation.13 Ecallantide has a high affinity
and specificity for human plasma kallikrein, a key enzyme
in contact activation of the coagulation cascade and com-
plement activation of the inflammatory cascade.13 Ecallan-
tide and aprotinin are of the same class of drugs known as
Kunitz protease inhibitors that have been shown in animal
models to reduce post-CPB blood loss.14 Aprotinin is
a broad-spectrum protease inhibitor 15 and a more potent
plasmin inhibitor than ecallantide, which is desirable during
CPB to decrease fibrinolysis but less desirable postopera-
tively and, in theory, may contribute to the thrombotic com-
plications associated with aprotinin.16,17 Aprotinin is
derived from animal protein, making it immunogenic,
whereas ecallantide is recombinant, derived from human
protein with less potential for antigenicity.15
Ecallantide’s ability to attenuate the inflammatory re-
sponse during CPB and to decrease consumption of coagu-
lation factors during CPB and bradykinin-mediated
capillary leak support its investigation in cardiac surgery.18
Two pilot studies in 111 patients undergoing cardiac opera-
tions with CPB for primary coronary artery bypass grafting
(CABG) or single-valve surgery demonstrated ecallantide
safety and decreased perioperative transfusion of blood
products.19 Ecallantide was recently approved for market-
ing by the US Food and Drug Administration for treatment
of hereditary angioedema, supporting its anti-inflammatory
mechanism of action.
We describe the results of a phase 2 clinical trial designed
to evaluate the relative efficacy and safety of ecallantideThe Journal of Thoracic and Carcompared with tranexamic acid to reduce blood loss in pa-
tients undergoing cardiac surgery using CPB for operations
associated with a high risk of bleeding.MATERIALS AND METHODS
Study Design
This prospective, double-blind, randomized phase 2 trial was conducted
at 36 centers in 3 countries (Germany, 20 sites; Poland, 15 sites; and United
States, 1 site) between March and December 2009. The protocol was ap-
proved by the institutional review board of each study center, and all pa-
tients or legally authorized representatives provided written consent. The
study was designed jointly by Cubist Pharmaceuticals (Lexington, Mass)
and the investigators. Data were collected by the investigators and moni-
tored by a third-party contract research organization (Global Research Ser-
vices, Rockville, Md). Data analyses and biostatistics were performed by
an independent third party (InVentiv Clinical, Hunt Valley, Md). All au-
thors had full access to the data.
Patients
Eligible patients included men or women aged 18 years or more and 85
years or less undergoing cardiac surgery using CPB for one of the following
operations associated with a higher risk of bleeding: repeat sternotomy, sur-
gery to repair or replace more than 1 valve, or combined CABG plus repair
or replacement of at least 1 valve. Exclusion criteria were any off-pump
procedure; planned blood transfusion during the perioperative period;
weight less than 55 kg; planned hypothermia (<28C); pregnant or lactat-
ing women; ejection fraction less than 30%; myocardial infarction (MI)
within 5 days of surgery; stroke or transient ischemic attack within 3
months before surgery; hypotension or heart failure requiring the use of
inotropes or mechanical devices within 24 hours of surgery; creatinine
greater than 2.0 mg/dL within 48 hours of surgery; preoperative hepatic en-
zymes more than 2.5 times the upper limit of normal; hematocrit less than
32%; platelet count below normal range at site laboratory; history of bleed-
ing or clotting disorder; history of heparin-induced thrombocytopenia; pro-
thrombin time or activated partial thromboplastin time more than 1.5 times
the normal range unless receiving heparin; color blindness; evidence of
acute thromboses or thromboembolism; and use of antiplatelet drugs or an-
ticoagulants within prespecified times.
Baseline Data Collection and Randomization
Patients and all study personnel except the investigative pharmacist at
each site were blinded to treatment assignment. Eligible patients were ran-
domized 1:1 to ecallantide or tranexamic acid. All patients were centrally
randomized using an interactive voice-response system and a computer-
generated schedule. After consenting, screening assessments included
medical and surgical history, physical examination, and laboratory tests.
Anesthesia and surgery were conducted according to each institution’s
standard of care. All patients were given the same fixed loading dose of
heparin (300U/kg) and pump priming dose (10,000U). Additional heparin,
up to 100 U/kg, was given as needed to achieve an activated clotting time
(ACT) of more than 450 seconds. Because ecallantide may spuriously pro-
long the ACT, whole blood heparin concentration (WBHC) was monitored
to ensure adequate anticoagulation and preserve blinding. Study medica-
tion was not given until an ACT of more than 450 seconds had been
achieved, and the corresponding WBHC was the target concentration dur-
ing CPB. If necessary, additional boluses of 3000 to 5000 units were given
to maintain target heparin concentration while on CPB. WBHC was mea-
sured at a minimum of every 30 minutes.
To standardize transfusion practice across institutions and minimize
variability that might confound study results, the protocol included the
transfusion guidelines from The Society of Thoracic Surgeons Blood Con-
servation Guideline Task Force 2007.20 The investigators were instructeddiovascular Surgery c Volume 143, Number 5 1023
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nation in the case report form.
Study Drug Administration
After heparinization, a loading dose of ecallantide or tranexamic acid
was given on the basis of randomization. Ecallantide was administered as
a bolus infusion of 0.13mg/kgover 5 to 10minutes followedby a continuous
infusion of 0.14mg/kg/h. An additional 2.25mg of ecallantidewas added to
each liter of pump prime. For tranexamic acid, the original protocol used
a 30 mg/kg loading dose followed by a 16 mg/kg/h infusion during surgery
with 500 mg added to the pump prime. Polish sites treated 24 patients with
this higher dose of tranexamic acid. Subsequently, 85 patients randomized
to the tranexamic acid group in Poland, Germany, and the United States re-
ceived a lower dose of tranexamic acid consisting of a 1000-mg loading
dose followed by a continuous infusion of 400 mg/h with an additional
500 mg added to the pump prime. The protocol was amended to comply
with a request by the German regulatory authority (BfArM) to use the cur-
rently approved dose of tranexamic acid (Cyklokapron) marketed in Ger-
many for the indication to decrease bleeding from CPB.
Both drugs were diluted in normal saline at concentrations to give
equivalent infusion rates to maintain study blinding. Study drug was in-
fused throughout CPB and surgery until skin dressings were applied or
for a maximum of 6 hours, whichever came first.
Patients were monitored immediately before surgery (study day 1) to
study day 4 (1) and study day 7 (1) or discharge from the hospital
(whichever occurred first) and again 35 days (–7/þ14) after dosing. Assess-
ments included physical examination, vital signs, electrocardiogram, chest
tube drainage volume, transfusion requirements, and clinical laboratory
tests.
The study design included oversight of the safety of treatment by an in-
dependent Data Safety Monitoring Board (DSMB) and centrally blinded
(adjudicated) review of electrocardiograms and cardiac enzymes for eval-
uation of MI. The DSMB independently and prospectively wrote a charter
with stopping rules.
Outcome Measures and Safety End Points
The key efficacy variables of interest were the volume of packed red
blood cells (PRBCs) and volume of blood products (eg, platelets and
fresh-frozen plasma [FFP]) administered from the start of surgery up to
12 hours after the end of surgery. These variables were also assessed 24
hours postsurgery and before hospital discharge. Other clinical outcome
variables were cumulative volume of chest tube drainage at 12 and 24 hours
after surgery, changes in serum creatinine, and adjudicatedMI. Exploratory
analyses included the incidence of massive bleeding, defined as any one of
the following events within 24 hours of the end of surgery: chest tube drain-
age more than 1.25 L in any 6-hour period, transfusion of more than 10
units of red cells in any 12-hour period from end of surgery, reexploration
of the chest for suspected bleeding or cardiac tamponade, or death from
hemorrhage within 30 days of surgery. Other exploratory analyses were
new-onset neurologic deficit and the incidence of renal failure, defined
as the requirement for dialysis, a doubling from baseline of serum creati-
nine, or any creatinine value greater than 1.7 mg/dL. Safety was assessed
from adverse events and changes in laboratory assessments or vital signs.
Statistical Analyses
The efficacy analyses were evaluated in themodified intent-to-treat pop-
ulation, defined as all randomized patients who received any amount of
study drug. A sample size of 298 patients, 149 in each treatment arm,
was determined to provide 80% power at the .05 significance level to detect
a decrease of 265 mL in red blood cells transfused in the ecallantide treat-
ment group compared with tranexamic acid from the start of surgery up to
12 hours after the end of surgery. Comparisons between the ecallantide and
tranexamic acid treatment groups used the Wilcoxon rank-sum test for1024 The Journal of Thoracic and Cardiovascular Survariables with a continuous outcome. Fisher exact test compared propor-
tions between treatment groups for variables with a dichotomous outcome.
All tests were 2-sided and conducted at the .05 significance level. There
were no inferential adjustments for multiplicity. All statistical analyses
were performed with SAS version 9.1.3 (SAS Institute, Inc, Cary, NC).
The safety of ecallantide treatment was evaluated in all randomized pa-
tients who received any amount of study drug. Evaluation of safety param-
eters was descriptive in nature.RESULTS
The study was terminated by the sponsor when the
DSMB recommended temporary suspension of enrollment.
During data review, the DSMB observed a statistically sig-
nificant difference in mortality rates between the treatment
arms. Although overall mortality was consistent with ex-
pected outcomes for the patient population, more deaths
were observed in the ecallantide arm. At the conclusion
of enrollment, 242 of the 300 planned patients had been ran-
domized, including 120 patients in the ecallantide group
and 122 patients in the tranexamic acid group. A total of
218 patients who received any amount of study drug com-
prised the modified intent-to-treat and safety population, in-
cluding 109 patients in both the ecallantide and tranexamic
acid groups (Figure 1).
The majority of treated patients (89%; 193/218) com-
pleted the study, including 84% (92/109) in the ecallantide
group and 93% (101/109) in the tranexamic acid group; 5%
(5/109) in each treatment group were reported as lost to
follow-up for the 35-day post-treatment visit. The number
of patients randomized and treated by country was 125
and 109 in Germany, 117 and 108 in Poland, and 1 and 1
in the United States. The treatment groups were comparable
in demographic and baseline characteristics (Table 1).
Table 2 presents the summary of surgical procedures.
Most patients underwent CABG with valve replacement,
primarily aortic valve and mitral valve. Mean duration of
CPB and aortic crossclamp time were similar in the ecallan-
tide and the tranexamic acid groups. Overall duration of sur-
gery was 304  99 (mean  standard deviation) minutes in
the ecallantide group and 310  85 minutes in the tranexa-
mic acid groups. Total heparin dose administered during
surgery was 45,500  12,000 and 47,800  15,180 units
in the ecallantide and tranexamic acid groups, respectively.
The total amount of study drug exposure was 48.06 mg
(0.61 mg/kg) of ecallantide, 5895.3 mg (73.7 mg/kg) for
the first 24 patients taking tranexamic acid who were en-
rolled under the initial protocol using the high dose and
2830.3 mg (35.4 mg/kg) for the 85 patients taking tranexa-
mic acid who were enrolled under the amended protocol
with the lower labeled dose of tranexamic acid.
Ecallantide was not as effective as tranexamic acid in
reducing blood loss in this study. Median cumulative vol-
ume of PRBCs administered through 12 hours postsurgery
was significantly higher in the ecallantide group,
median ¼ 900 mL (95% CI, 600–1070), compared withgery c May 2012
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FIGURE 1. CONSORT flow diagram.
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0–523; P<.001) (Figure 2). Furthermore, at all time points,
the cumulative volume of PRBCs administered was signif-
icantly higher in the ecallantide group compared with the
tranexamic acid group (P< .001 at 24 hours and at dis-
charge). Results were similar for transfusion of FFP and
platelets at 12 hours. The ecallantide group received signif-
icantly more FFP (median ¼ 521 mL; 95% CI, 0–877 vs
median ¼ 0 mL; 95% CI, 0–0 mL; P ¼ .002) and platelets
(mean ¼ 157 mL; median ¼ 0 mL; 95% CI, 0–0 mL vs
mean ¼ 83 mL; median ¼ 0 mL; 95% CI, 0–0;
P¼ .008) than the tranexamic acid group. Eighty-three per-
cent of the ecallantide group and 63% of the tranexamic
acid group received a red cell transfusion by 24 hours post-
surgery (P ¼ .002). Transfusion of PRBCs was statistically
greater for the ecallantide group compared with the tranexa-
mic acid group for the planned surgical groups listed in
Table 2, CABG/valve surgery (P<.001) and repair/replace-
ment of more than 1 valve (P ¼ .003), and numerically
greater than tranexamic acid for repeat sternotomy
(P ¼ .582).
A post hoc analysis of the cumulative volume of PRBCs
administered compared the 24 patients who received the
higher dose and the 85 patients who received the lowerThe Journal of Thoracic and Cardose of tranexamic acid (Figure 3). A significant dose effect
of tranexamic acid was observed, with a higher cumulative
volume of PRBCs transfused to the 85 patients who re-
ceived the lower labeled dose of tranexamic acid compared
with the 24 patients who received the higher dose of tra-
nexamic acid. Median cumulative volume of PRBCs ad-
ministered through 12 hours postsurgery was 400 mL
(95% CI, 280–600) in the tranexamic acid lower-dose
group compared with 0 mL (95% CI, 0–400) in the
higher-dose group (P ¼ .008). Similar results were ob-
served at 24 hours, but there was no difference between
groups at discharge (Figure 3). Platelet transfusions were
also significantly lower in the high-dose tranexamic acid
group compared with the low-dose group at 12 (P ¼ .015)
and 24 (P ¼ .009) hours post-CPB. No patients in the
high-dose group experienced massive bleeding (as defined
above) compared with 16.5% (14/85) in the low-dose tra-
nexamic acid group (P ¼ .036). There were no deaths in
the high-dose group; the 4 tranexamic acid deaths occurred
in the low-dose group.
Safety
All-cause 30-daymortality was significantly higher in the
ecallantide group, with 12% of patients (13/109) versus 4%diovascular Surgery c Volume 143, Number 5 1025
TABLE 1. Demographic and baseline characteristics (safety
population)
Characteristic Ecallantide Tranexamic acid Total
N 109 109 218
Age, y 69.6  8.2 66.8  10.8 68.2  9.7
Gender, M/F 68/41 67/42 135/85
Race, n (%)
Caucasian 109 (100%) 109 (100%) 218 (100%)
Weight, kg 78.3  13.2 81.0  15.7 79.6  14.5
Height, cm 167.6  9.3 168.8  9.1 168.2  9.2
BMI, kg/m2 27.8  3.7 28.4  4.6 28.1  4.2
Smoking history, n (%)
No 46 (42.2%) 55 (50.5%) 101 (46.3%)
Yes 63 (57.8%) 54 (49.5%) 117 (53.7%)
Ongoing* 8 (12.7%) 10 (18.5%) 18 (15.4%)
Quit* 55 (87.3%) 44 (81.5%) 99 (84.6%)
Coexisting illness
Hypertension 91 (83.4%) 85 (78.0%) 176 (80.7%)
Diabetes mellitus 36 (33.0%) 28 (25.7%) 64 (29.4%)
Atrial fibrillation 25 (22.9%) 36 (33.0%) 61 (28.0%)
Previous MI 20 (18.3%) 10 (9.2%) 30 (13.8%)
COPD 18 (16.5%) 11 (10.1%) 29 (13.3%)
Previous stroke 12 (11.0%) 9 (8.3%) 21 (9.6%)
Previous TIA 0 (0%) 1 (0.9%) 1 (0.5%)
Liver disease 9 (8.3%) 4 (3.7%) 13 (6.0%)
DVT 0 (0%) 3 (2.8%) 3 (1.4%)
Values presented as mean  standard deviation. BMI, Body mass index; COPD,
chronic occlusive pulmonary disease; TIA, transient ischemic attack; DVT, deep
vein thrombosis. *Percentage based on patients with a history of smoking.
TABLE 2. Summary of the surgical procedure (safety population)
Surgical information
Ecallantide
(N ¼ 109)
Tranexamic acid
(N ¼ 109)
Planned surgery performed, n (%)
CABG plus replace  1
valve
75 (68.8) 76 (70.4)
Replace>1 valve 23 (21.1) 18 (16.7)
Repeat sternotomy 16 (14.7) 15 (13.9)
Type of surgery performed,* n (%)
Aortic valve replacement 70 (64.2) 81 (74.3)
CABG plus valve 71 (65.1) 71 (65.1)
Mitral valve replacement 16 (14.7) 22 (20.2)
Mitral valve repair 22 (20.2) 11 (10.1)
Tricuspid valve repair 12 (11.0) 11 (10.1)
Aortic valve repair 6 (5.5) 6 (5.5)
Repeat CABG 8 (7.3) 2 (1.8)
Pulmonary valve
replacement
2 (1.8) 3 (2.8)
Tricuspid valve
replacement
0 1 (0.9)
Other 13 (11.9) 19 (17.4)
Duration of CPB (min)
N 109 109
Mean (SD) 128.8 (65.09) 129.6 (50.94)
Median 113.0 120.0
Minimum, maximum 43, 445 43, 358
Duration of aortic crossclamp (min)
N 109 108
Mean (SD) 88.8 (49.27) 88.1 (34.58)
Median 79.0 81.0
Minimum, maximum 24, 396 27, 209
Duration of surgery (min)y
N 106 109
Mean (SD) 303.5 (98.68) 310.0 (84.90)
Median 283.0 297.0
Minimum, maximum 165, 730 139, 650
Total heparin dose (1000 U)
N 109 109
Mean (SD) 45.5 (12.03) 47.8 (15.18)
Median 43.5 45.0
Minimum, maximum 25.0, 92.5 26.0, 117.1
SD, Standard deviation. *More than 1 type of surgery may have been planned/per-
formed for a given patient. yThe time from induction of anesthesia through dressing
applied.
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3). No death was considered related to the study drug by the
reporting investigator or DSMB. Nine of the 17 deaths
(53%) occurred in the immediate postsurgical period (by
the second postoperative day). All patients who died in
the tranexamic acid group received the lower dose of tra-
nexamic acid.
Serious adverse events were reported in 41% of patients
(45/109) who received ecallantide compared with 26% of
patients (28/109) who received tranexamic acid, possibly
attributable to more reports of hemorrhage in the ecallantide
group. Massive postoperative bleeding occurred in 26% of
the ecallantide group (28/109) and 13% of the tranexamic
acid group (14/109) (P ¼ .025). No patients receiving the
higher dose of tranexamic acid experienced massive bleed-
ing. The number of patients requiring reexploration for
massive bleeding was also significantly higher in the ecal-
lantide group (18%; 20/109) compared with the tranexamic
acid group (8%; 9/109; P ¼ .045), as was the proportion of
patients with chest tube drainage exceeding 1.25 L in 6
hours; 14% (15/109) versus 6% (7/109; P ¼ .038). Renal
failure was reported in 6% of the ecallantide group (6/
104) and 12% of the tranexamic acid group (13/109)
(P¼ .150). AdjudicatedMI occurred in 23% of the ecallan-
tide group (25/109) and 21% of the tranexamic acid group1026 The Journal of Thoracic and Cardiovascular Sur(23/109) (P ¼ .869). Postoperative troponin T concentra-
tions were greater than 1.2 mg/L in 39.6% of patients (42/
106) in the ecallantide group compared with 35.8% of pa-
tients (39/109) in the tranexamic acid group (P ¼ .576).
There was no difference between groups in postoperative
CK-MB concentrations. Prolonged ventilation, days on ino-
tropic support, and new-onset neurologic deficits also were
not statistically different between treatment groups. Three
patients were reported to have seizures; all received the
low dose of tranexamic acid. Two patients in each of the
treatment groups had the study drug discontinued because
of adverse events: cardiac failure in the operating room ingery c May 2012
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FIGURE 2. Mean cumulative volume of PRBCs transfused during sur-
gery through hospital discharge. ***P<.001 for comparison between treat-
ment groups (Wilcoxon rank-sum test). CI, Confidence interval; PRBC,
packed red blood cell.
TABLE 3. Summary of deaths
Treatment Surgery Cause of death
ECAL CABG/AVR (3) Cardiogenic shock (5)
CABG/MVR (3) Cardiogenic shock/bleeding (2)
AVR/MVR (3) Cardiogenic shock/sepsis (1)
Resternotomy/
CABG/AVR/MVR (2)
Cardiac arrest (1)
Resternotomy/CABG (1) Sepsis (1)
Resternotomy/AVR (1) Respiratory failure (1)
Ventricular rupture (1)
MSOF/hemorrhage (1)
TXA CABG/AVR/MVR (1) Cardiogenic shock (1)
CABG/MVR/TVR (1) Cardiogenic shock/bleeding (1)
Resternotomy/
CABG/AVR (1)
MSOF/sepsis
Resternotomy/MVR (1) Tamponade/septic shock/stroke
ECAL, Ecallantide; TXA, tranexamic acid; AVR, aortic valve repair or replacement;
MVR, mitral valve repair or replacement; TVR, tricuspid valve repair; MSOF, multi-
system organ failure.
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lantide group; ventricular tachycardia in 1 patient and mul-
tiorgan failure in 1 patient in the tranexamic acid group.DISCUSSION
In this trial, tranexamic acid significantly decreased post-
operative blood loss and need for allogeneic transfusions
compared with ecallantide. Ecallantide-treated patients re-
quired larger volumes of PRBCs in the postoperative period
compared with tranexamic acid-treated patients (Figure 2).
The incidence of massive postoperative bleeding was higher
in the ecallantide group (26%) than in the tranexamic group0
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FIGURE 3. The effect of tranexamic dose on transfusion of PRBC. P
values based on the Wilcoxon rank-sum test. CI, Confidence interval;
PRBC, packed red blood cell.
The Journal of Thoracic and Car(13%; P ¼ .025). In addition, there was a higher mortality
rate in the ecallantide group (12%) than in the tranexamic
acid group (4%, P¼ .041), prompting the early termination
of the study (Table 3). Another finding of this trial was that
the higher dose of tranexamic acid was significantly more
effective than the labeled dose at decreasing blood loss
without increasing adverse events. Seizures, massive bleed-
ing, reexploration for bleeding, and deaths occurred only in
the low-dose tranexamic acid group.
Why ecallantide was less effective than tranexamic acid
is not clear but may be related to ecallantide’s relative lack
of plasmin inhibition. Nonclinical assays estimated that
ecallantide, at the dose used in this trial, would result in
similar plasmin inhibition to tranexamic acid.14 Tranexa-
mic acid is a synthetic derivative of the amino acid lysine
that exerts its antifibrinolytic effect by reversibly blocking
lysine binding sites on plasminogen molecules.21 In con-
trast, ecallantide indirectly mitigates fibrinolysis and
plasmin generation by inhibiting contact activation via
kallikrein inhibition. The failure of ecallantide to decrease
bleeding in this trial not only suggests that plasmin
inhibition is essential to decrease bleeding after CPB but
also implies that the mechanism of plasmin inhibition
is equally important. Inhibiting plasma kallikrein seems
to have little, if any, effect on fibrinolysis as previously
suggested.22,23 This concept is supported by aprotinin’s
greater inhibition of tissue kallikrein than plasma kallikrein
and its direct plasmin inhibition, possibly potentiating its
antifibrinolytic effects.14,22,23
Aprotinin and tranexamic acid also interact with tissues
and organs through uncharacterized pathways that could
contribute to their efficacy in decreasing bleeding.17 The
mechanisms by which aprotinin is so effective at decreasing
CPB-associated blood loss have never been clearly defined.
Aprotinin is a broad-spectrum protease inhibitor thatdiovascular Surgery c Volume 143, Number 5 1027
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with CPB surgery. The effects of aprotinin use during
CPB may involve a reduction in inflammatory response
that translates into reduced bleeding, decreased need for al-
logeneic blood transfusions, and decreased mediastinal re-
exploration for bleeding.24 However, the results of the
present trial do not support the concept that the inflamma-
tory response from CPB is a major mediator of post-CPB
bleeding. Ecallantide’s lack of effect on blood loss and
transfusion compared with tranexamic acid in this patient
population suggests that inhibiting kallikrein-mediated ef-
fects on complement activation and the inflammatory re-
sponse to CPB has little impact on perioperative bleeding.
Although complement and inflammatory mediators were
not assessed in this trial, this assumption is based on the
known activity of ecallantide on plasma kallikrein, inhibi-
tion of bradykinin, and modulation of inflammatory media-
tors, as well as animal CPB models that demonstrated
decreased expression of inflammatory mediators.13,18
Ecallantide is approved for and effective at treating life-
threatening hereditary angioedema, a bradykinin and
complement-mediated inflammatory response.13 Ecallan-
tide doses used to treat hereditary angioedema are lower
than those used in the present trial and effectively inhibit
kallikrein-mediated inflammation.25
Although inhibiting CPB-induced inflammation may not
decrease post-CPB bleeding, there may be beneficial effects
of kallikrein inhibition on reperfusion injury. Despite nearly
twice the transfusion requirements in the ecallantide group,
the incidence of postoperative MI, renal dysfunction, ino-
tropic support, and prolonged mechanical ventilation were
the same or less than in the tranexamic acid group. Postop-
erative CK-MB and troponin T concentrations were similar
between groups. Although bleeding and transfusion
strongly correlate with organ dysfunction, this was not ob-
served in this trial. Consumptive coagulopathy is another
proposed mechanism of post-CPB bleeding.26 Contact acti-
vation of the blood during CPB converts prekallikrein to
kallikrein, initiating the intrinsic pathway of coagulation.
Preserving coagulation factors during CPB by blocking
the intrinsic pathway consumption of these factors did not
have the predicted effect of improved post-CPB coagula-
tion. However, it is not clear from this trial whether the latter
was due to decrease in clot formation, increased clot degra-
dation from plasmin, or both.
The high dose of tranexamic acid used in this trial was
similar to that used in the Blood Conservation Using Anti-
fibrinolytics in a Randomized Trial (BART) study,27 30 mg/
kg/loading dose and continuous infusion at 16 mg/kg/h. A
similar population of patients at high risk for bleeding
was studied in both trials. In the BART study, 12.1% of pa-
tients (93/770) had massive bleeding using the same defini-
tion as the present study, and the 30-day all-cause mortality
rate was 3.9%. Likewise, the present study had a massive1028 The Journal of Thoracic and Cardiovascular Surbleeding rate of 13% and 30-day all cause mortality of
4% for all patients receiving tranexamic acid. However,
massive bleeding and death occurred only in those patients
receiving the lower dose of tranexamic acid, which was ap-
proximately half of the high dose.CONCLUSIONS
Ecallantide was not as effective as tranexamic acid in re-
ducing blood loss in this study. There were significantly
more deaths and massive bleeding events in ecallantide-
treated patients than in tranexamic acid-treated patients.
The higher dose of tranexamic acid was more effective
than the currently labeled dose of tranexamic acid at de-
creasing blood loss and massive bleeding events.References
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